Eric Francois was appointed Director of 60 Degrees Pharmaceuticals, Inc. As of November 6, 2026, 60 Degrees Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 18, 2026, naming 1 appointment (Form 8-K, May 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like 60 Degrees Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
60 Degrees Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-18. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as 60 Degrees Pharmaceuticals, Inc. files it.
Also on the record for 60 Degrees Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 5, 2026 | Stake report, Schedule 13G, by Lind Global Fund III LP | 5.45% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by Knight Therapeutics Inc. | 19.85% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Knight Therapeutics Inc. | — | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.1% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | 4.14% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| July 22, 2025 | Stake report, Schedule 13G, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by Orca Capital AG | 9.9% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs 60 Degrees Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on 60 Degrees Pharmaceuticals, Inc. and the records around it.
60 Degrees Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Watch 60 Degrees Pharmaceuticals, Inc.
Get an email when 60 Degrees Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 60 Degrees Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 60 Degrees Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 60 Degrees Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-18 | In | Director | 8-K, 2026-05-18 |
Who leads 60 Degrees Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Eric Francois, appointed (filed 2026-05-18).
New leaders reset buying decisions — get the Full Report on 60 Degrees Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at 60 Degrees Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at 60 Degrees Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Eric Francois, Director
On May 13, 2026, the Board of Directors (the "Board") of 60 Degrees Pharmaceuticals, Inc. (the "Company") appointed Eric Francois to serve as a member of the Board, effective immediately.
- Mr. Francois is a strategic financial executive with over 20 years of leadership experience in the healthcare and life sciences sectors.
- He currently serves as an Independent Director of CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) and as an independent strategic advisor to emerging life sciences companies.
- Mr. Francois previously served as Managing Director in Healthcare Investment Banking at Raymond James and Credit Suisse, where he led numerous equity, debt, and M&A transactions for small- and mid-cap biotechnology companies.
- Prior to his investment banking roles, he was Chief Financial Officer of SCYNEXIS, Inc. (Nasdaq: SCYX), where he oversaw finance, corporate development, investor relations, and operations, and raised over $300 million in capital to support the company's growth through FDA approval and commercial launch.
- He has also served as an independent director of Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), including roles on its Audit and Compensation Committees.
- Mr. Francois began his career in equity capital markets at Cowen & Company and Lazard Fr res and holds M.A. and B.A. degrees in business and economics from the Sorbonne University in Paris.
Tools for this story
Each opens in a new tab, filled in for 60 Degrees Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.